{"entity":{"id":"nct06187402","kind":"trial","name":"A Study of LM-24C5 For Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","summary":"A Study of LM-24C5 For Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06187402 by LaNova Medicines Limited, with 49 participants planned, started 2023-12-20 and due to reach its primary completion in 2026-06-30. Interventions recorded: LM-24C5.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06187402","url":"https://clinicaltrials.gov/study/NCT06187402"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06187402","phase":"1/2","setting":"A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","enrolled":49,"outcomes":[]},"route":"/trials/nct06187402/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}